FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2972459002> ?p ?o ?g. }

• W2972459002 endingPage "E523" @default.
• W2972459002 startingPage "E523" @default.
• W2972459002 abstract "There is increasing interest in treating oligometastatic non-small cell lung cancer (NSCLC) with stereotactic radiation. We aimed to address whether patients with NSCLC who were treated with synchronous thoracic stereotactic body radiation therapy (SBRT) and brain stereotactic radiosurgery (SRS) had favorable outcomes with local therapy alone. We reviewed an institutional review board-approved prospective database of patients receiving thoracic SBRT between June 2004 and January 2016 for those with cT1-2aN0 NSCLC as well as a database for brain metastasis patients treated with SRS. All patients opted in and signed an informed consent document for inclusion. Oligometastatic patients had thoracic SBRT and brain SRS within 90 days. Their overall survival (OS), freedom from progression (FFP), and both thoracic and brain local control (LC) were calculated from the date of first radiation therapy fraction and compared to outcomes for cT1-2aN0M0 patients. Patients who died of causes other than disease progression or treatment complications were censored and not counted as progression or local failure. Six patients had oligometastatic NSCLC with 1-3 synchronous brain metastases treated with lung SBRT and brain SRS. 645 patients had stage I NSCLC treated with lung SBRT alone. None of the oligometastatic patients had immunotherapy and two-thirds did not receive systemic therapy. Median follow-up was 24 months (range, 1-153 months) for the stage I group and 9 months for oligometastatic group (range, 2-95 months). Median OS was 41 months (95% confidence interval [CI], 37-45 months) in the stage I group compared to 12 months (95% CI, 5-18 months) in the oligometastatic group. At 1 year, stage I patients had 86% OS (95% CI, 83-89%), 80% FFP (95% CI, 77-84%), and 92% LC (95% CI, 90-95%). At 1 year, oligometastatic patients had similar OS (50% [95% CI, 10-90%, P=0.18]) and LC (100% [P=0.51]) with decreased FFP (17% [95% CI, 0-47%, P<0.001]). Their brain disease had 80% 1-year LC (95% CI, 45-100%) and 53% 1-year FFP (95% CI, 5-100%). The 5-year OS in the oligometastatic group was 17% (95% CI, 0-47%). Two of the patients had no distant progression: one remains alive at 95 months and the other died at 1.8 months. Of the remaining patients, two had progression in their brain at 2.3 and 10.1 months, one had progression to their adrenal gland at 6.8 months, and one had progression to their vertebrae, femur, and liver at 5.7 months. In patients presenting with oligometastatic lung cancer limited to the brain who are not candidates for systemic or immune therapy, aggressive treatment with both lung SBRT and brain SRS achieves good LC of all sites with encouraging OS. We observed no statistically significant difference in OS compared to patients with stage I disease, though this is limited by patient numbers." @default.
• W2972459002 created "2019-09-19" @default.
• W2972459002 creator A5002507883 @default.
• W2972459002 creator A5018706204 @default.
• W2972459002 creator A5022672770 @default.
• W2972459002 creator A5051570421 @default.
• W2972459002 creator A5066404810 @default.
• W2972459002 creator A5079247332 @default.
• W2972459002 creator A5083473334 @default.
• W2972459002 date "2019-09-01" @default.
• W2972459002 modified "2023-10-04" @default.
• W2972459002 title "Long-Term Survival without Systemic and Immune Therapy after Synchronous Thoracic and Brain Stereotactic Radiation for Oligometastatic NSCLC" @default.
• W2972459002 doi "https://doi.org/10.1016/j.ijrobp.2019.06.2419" @default.
• W2972459002 hasPublicationYear "2019" @default.
• W2972459002 type Work @default.
• W2972459002 sameAs 2972459002 @default.
• W2972459002 citedByCount "0" @default.
• W2972459002 crossrefType "journal-article" @default.
• W2972459002 hasAuthorship W2972459002A5002507883 @default.
• W2972459002 hasAuthorship W2972459002A5018706204 @default.
• W2972459002 hasAuthorship W2972459002A5022672770 @default.
• W2972459002 hasAuthorship W2972459002A5051570421 @default.
• W2972459002 hasAuthorship W2972459002A5066404810 @default.
• W2972459002 hasAuthorship W2972459002A5079247332 @default.
• W2972459002 hasAuthorship W2972459002A5083473334 @default.
• W2972459002 hasBestOaLocation W29724590021 @default.
• W2972459002 hasConcept C121608353 @default.
• W2972459002 hasConcept C126322002 @default.
• W2972459002 hasConcept C126838900 @default.
• W2972459002 hasConcept C143998085 @default.
• W2972459002 hasConcept C146357865 @default.
• W2972459002 hasConcept C151730666 @default.
• W2972459002 hasConcept C2776256026 @default.
• W2972459002 hasConcept C2778164965 @default.
• W2972459002 hasConcept C2779013556 @default.
• W2972459002 hasConcept C2780387249 @default.
• W2972459002 hasConcept C509974204 @default.
• W2972459002 hasConcept C71924100 @default.
• W2972459002 hasConcept C86803240 @default.
• W2972459002 hasConceptScore W2972459002C121608353 @default.
• W2972459002 hasConceptScore W2972459002C126322002 @default.
• W2972459002 hasConceptScore W2972459002C126838900 @default.
• W2972459002 hasConceptScore W2972459002C143998085 @default.
• W2972459002 hasConceptScore W2972459002C146357865 @default.
• W2972459002 hasConceptScore W2972459002C151730666 @default.
• W2972459002 hasConceptScore W2972459002C2776256026 @default.
• W2972459002 hasConceptScore W2972459002C2778164965 @default.
• W2972459002 hasConceptScore W2972459002C2779013556 @default.
• W2972459002 hasConceptScore W2972459002C2780387249 @default.
• W2972459002 hasConceptScore W2972459002C509974204 @default.
• W2972459002 hasConceptScore W2972459002C71924100 @default.
• W2972459002 hasConceptScore W2972459002C86803240 @default.
• W2972459002 hasIssue "1" @default.
• W2972459002 hasLocation W29724590021 @default.
• W2972459002 hasOpenAccess W2972459002 @default.
• W2972459002 hasPrimaryLocation W29724590021 @default.
• W2972459002 hasRelatedWork W2064553745 @default.
• W2972459002 hasRelatedWork W2357126231 @default.
• W2972459002 hasRelatedWork W2369094418 @default.
• W2972459002 hasRelatedWork W2372557636 @default.
• W2972459002 hasRelatedWork W2376213003 @default.
• W2972459002 hasRelatedWork W2378131018 @default.
• W2972459002 hasRelatedWork W2380658010 @default.
• W2972459002 hasRelatedWork W2388910868 @default.
• W2972459002 hasRelatedWork W2402345276 @default.
• W2972459002 hasRelatedWork W3007968561 @default.
• W2972459002 hasVolume "105" @default.
• W2972459002 isParatext "false" @default.
• W2972459002 isRetracted "false" @default.
• W2972459002 magId "2972459002" @default.
• W2972459002 workType "article" @default.